Jiangsu Bioperfectus Technologies Co

Jiangsu Bioperfectus Technologies Co EBITDA per Share

The EBITDA per Share of Jiangsu Bioperfectus Technologies Co (688399.SS) as of Nov 2, 2026 is -0.31 CNY. In the previous year, EBITDA per Share was 0.33 CNY — a change of -195.63% (lower).

EBITDA per Share

-0.31CNY

YoY

-195.63%

Last updated:

EBITDA per Share of Jiangsu Bioperfectus Technologies Co is 2025 -0.31 CNY. EBITDA per Share of Jiangsu Bioperfectus Technologies Co was 2024 0.33 CNY. It decreases by -195.63% lower compared to the previous year.

The Jiangsu Bioperfectus Technologies Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
1.32 CNY
Jan 1, 2019
1.53 CNY
Jan 1, 2020
11.31 CNY
Jan 1, 2021
16.46 CNY
Jan 1, 2022
25.46 CNY
Jan 1, 2023
-3.61 CNY
Jan 1, 2024
0.33 CNY
Jan 1, 2025
-0.31 CNY
The Jiangsu Bioperfectus Technologies Co EBITDA per Share history
YEAREBITDA per ShareYoY
-0.31CNY-195.63%
0.33CNY-109.01%
-3.61CNY-114.19%
25.46CNY+54.69%
16.46CNY+45.53%
11.31CNY+638.63%
1.53CNY+15.86%
1.32CNY+125.43%
0.59CNY+339.24%
0.13CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jiangsu Bioperfectus Technologies Co Stock analysis

What does Jiangsu Bioperfectus Technologies Co do? Jiangsu Bioperfectus Technologies Co., Ltd. generates revenue through the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company's primary products include in vitro diagnostic reagents, supporting testing instruments, and in vitro testing services, which are utilized in infectious disease prevention and control, clinical testing, large-scale population screening, and prenatal and postnatal care management. Domestic and overseas markets represent the main sales channels for these products, with the firm targeting healthcare providers and laboratories that require diagnostic solutions for disease detection and patient care. The company's focus on in vitro diagnostic reagents and supporting instruments positions it within the healthcare sector, serving customers who need reliable testing tools for clinical and public health applications. By offering comprehensive diagnostic solutions, Jiangsu Bioperfectus addresses the needs of medical institutions and public health initiatives, particularly in areas such as infectious disease management and maternal care. The firm's product portfolio supports both routine clinical testing and specialized population screening programs. Jiangsu Bioperfectus Technologies Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jiangsu Bioperfectus Technologies Co stock

EBITDA per Share of Jiangsu Bioperfectus Technologies Co is -0.31 CNY in 2025.

EBITDA per Share of Jiangsu Bioperfectus Technologies Co changed from 0.33 CNY to -0.31 CNY, representing a -195.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Jiangsu Bioperfectus Technologies Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Jiangsu Bioperfectus Technologies Co

All Key Metrics — Jiangsu Bioperfectus Technologies Co